Cost-effectiveness analysis of anticoagulation strategies in non-ST-elevation acute coronary syndromes

Annals of Pharmacotherapy

Volumn 43, Issue 4, 2009, Pages 586-595

  Maxwell, Carleton B ^a   Holdford, David A ^b   Crouch, Michael A ^c,d   Patel, Dipen A ^b  

^a Jackson Madison County General Hospital   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c SOUTHERN UNIVERSITY   (United States)

^d NONE   (United States)

Author keywords

Acute coronary syndrome; Bivalirudin; Cost effectiveness; Fondaparinux; Low molecular weight heparin; Unfractionated heparin

Indexed keywords

ENOXAPARIN; EPTIFIBATIDE; FONDAPARINUX; HEPARIN; HIRULOG;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSIS RELATED GROUP; DRUG COST; DRUG UTILIZATION; ERYTHROCYTE TRANSFUSION; HEALTH CARE PERSONNEL; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MONOTHERAPY; PRIORITY JOURNAL; PROBABILITY; SENSITIVITY ANALYSIS; ST SEGMENT ELEVATION; TREATMENT OUTCOME;

EID: 65749087052     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L498     Document Type: Article

References (18)

1. Heart disease and stroke statistics - 2008 update. Circulation 2008;117: e25-146.2.
2. Angina/non-ST-elevation myocardial infarction: executive summary: a report. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction. Circulation 2007;116;803-877
3. Hirsh J, Guyatt G, Albers GW, et al. Executive summary: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed). Chest 2008;133:71S-105S.
4. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA 1996;276:811-815
5. Cohen M, Demers C, Gurfinkle EP, et al. A comparison of low-molecular-weight heparins with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447-452
6. Antman EM, McCabe CH, Gurfinkle EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Circulation 1999;100:1593-1601
7. SYNERGY trial investigators. Enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy. JAMA 2004;292:45-54.
8. Cohen M, Mahaffey K, Pieper K, et al. A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial. J Am Coll Cardiol 2006;48:1346-1354
9. The Fifth Organization to Assess Strategies in Acute Ischemic Syndrome Investigators, Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006;354:1464-1476
10. Mehta S, Granger C, Eikelboom J, et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 study. J Am Coll Cardiol 2007;50:1742-1751 (Pubitemid 47600591)
11. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndrome. N Engl J Med 2006;355:2203-2216
12. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, et al. Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987; 76:142-154
13. Intellimed International Corporation. Myhealthscore.com: the online coder. www.myhealthscore.com (accessed 2007 Oct 25).
14. Summers KM, Holdford DA, Crouch MA. Cost-effectiveness analysis of antithrombotic therapy in nonurgent percutaneous coronary intervention. Pharmacotherapy 2006;26:609-618 (Pubitemid 43673043)
15. Borg S, Persson U, Allikmets K, Ericsson K. Comparative cost-effectiveness of anticoagulation with bivalirudin or heparin with and without a glycoprotein IIb/IIIa-receptor inhibitor in patients undergoing percutaneous coronary intervention in Sweden: a decision-analytic model. Clin Ther 2006;28:1947-1959. (Pubitemid 46043509)
16. Mishkel GJ, Moore AL, Markwell SJ, Ligon RW. Bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in drug-eluting stent implantations in the absence of acute myocardial infarction: clinical and economic results. J Invasive Cardiol 2007;19:63-68
17. Huston SA, Hawkins D. Pharmacoeconomics of anticoagulants in acute coronary syndrome and percutaneous coronary intervention. Curr Pharm Des 2008;14:1197-1204
18. 2007 Focused update of the ACC/AHA/SCI 2005 guideline update for percutaneous coronary intervention. J Am Coll Cardiol 2008;51:172-209.